Accéder au contenu
Merck
Toutes les photos(2)

Documents

B102

Sigma-Aldrich

Bupropion hydrochloride

≥98% (HPLC), solid, dopamine and norepinephrine transporter inhibitor

Synonyme(s) :

(±)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C13H18ClNO · HCl
Numéro CAS:
Poids moléculaire :
276.20
Numéro CE :
Numéro MDL:
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.77

product name

Bupropion hydrochloride, ≥98% (HPLC), solid

Niveau de qualité

Pureté

≥98% (HPLC)

Forme

solid

Couleur

white

Solubilité

H2O: 15 mg/mL, clear

Auteur

GlaxoSmithKline

Chaîne SMILES 

Cl[H].CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

Clé InChI

HEYVINCGKDONRU-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Bupropion is structurally linked to the phenylethylamine family. It is a monocyclic aminoketone (chloropropiophenone).

Application

Bupropion hydrochloride has been used as an anti-depressant and injected into mice intraperitoneally for forced swim test. It has also been used to study its effects on depression, anxiety and smoking cessation.

Actions biochimiques/physiologiques

Bupropion possesses antidepressant and anxiolytic properties. It serves as a good auxiliary for people who makes an effort to give up smoking. It may also be used in the treatment for attention-deficit hyperactivity disorder.
Inhibits the dopamine and norepinephrine transporters with Kis of 2.8 μM and 1.4 μM, respectively. Does not inhibit the serotonin transporter (Ki = 45 μM). Antidepressant.

Caractéristiques et avantages

This compound is a featured product for ADME Tox and Neuroscience research. Discover more featured ADME Tox and Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

B R Cooper et al.
The Journal of pharmacology and experimental therapeutics, 215(1), 127-134 (1980-10-01)
Bupropion (BW 323U; Wellbutrin), a novel compound with antidepressant effects in man, was found to reduce immobility in an "experimental helplessness" forced swimming antidepressant test in rats as did imipramine and amitriptyline. Higher doses produced elevated locomotor activity in an
Jinhui Wang et al.
Frontiers in pharmacology, 11, 593518-593518 (2021-03-23)
Poziotinib is an orally active, irreversible, pan-HER tyrosine kinase inhibitor used to treat non-small cell lung cancer, breast cancer, and gastric cancer. Poziotinib is currently under clinical investigation, and understanding its drug-drug interactions is extremely important for its future development
Chronic ethanol potentiates the effect of neuropeptide s in the basolateral amygdala and shows increased anxiolytic and anti-depressive effects
Enquist J, et al.
Neuropsychopharmacology, 37(11), 2436-2436 (2012)
Kyla H Thomas et al.
BMJ (Clinical research ed.), 347, f5704-f5704 (2013-10-15)
To compare the risk of suicide, self harm, and depression in patients prescribed varenicline or bupropion with those prescribed nicotine replacement therapy. Prospective cohort study within the Clinical Practice Research Datalink. 349 general practices in England. 119,546 men and women
Sonia M Grandi et al.
The Canadian journal of cardiology, 29(12), 1704-1711 (2013-11-26)
Smoking remains the most important modifiable risk factor for secondary prevention of cardiovascular events. We therefore performed a meta-analysis to determine the efficacy and safety of bupropion therapy started in-hospital for smoking cessation in patients with cardiovascular disease (CVD). We

Articles

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Afficher tout

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique